{"id":391371,"date":"2015-06-29T00:00:00","date_gmt":"2015-06-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorcg0615-biopharma-unipolar-depression-pharmacor-g7-2015\/"},"modified":"2026-04-22T05:27:41","modified_gmt":"2026-04-22T05:27:41","slug":"pcorcg0615-biopharma-unipolar-depression-pharmacor-g7-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorcg0615-biopharma-unipolar-depression-pharmacor-g7-2015\/","title":{"rendered":"Unipolar Depression | Pharmacor | G7 | 2015"},"content":{"rendered":"<p><em>Last Updated 29 June 2015<\/em><br \/>\nUnipolar depression\u2014comprising major depressive disorder (MDD), minor depression, and dysthymia\u2014is a highly prevalent psychiatric disorder affecting nearly 85 million individuals in the seven major markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Throughout our 2014-2024 study period, the unipolar depression therapy market will consist almost entirely of generic products that dominate treatment, particularly in the early lines. Only a few branded products\u2014namely Actavis\u2019s vilazodone (Viibryd), Lundbeck\/Takeda Pharmaceutical\u2019s vortioxetine (Brintellix), Actavis\/Pierre Fabre\u2019s levomilnacipran (Fetzima), Otsuka Pharmaceutical\/Lundbeck\u2019s brexpiprazole, Actavis\/Gedeon Richter\/Mitsubishi Tanabe Pharma\u2019s cariprazine, Sumitomo Dainippon\/Sunovion\/Takeda Pharmaceutical\u2019s lurasidone (Latuda), Alkermes\u2019s ALKS-5461, and Naurex\u2019s rapastinel\u2014will be competing for market share during the forecast period in this highly genericized space. Because of generic competition from current therapies, it is unlikely that any emerging drugs will become dominating first-line treatments; however, low patient response rates and even lower remission rates following treatment with first-line therapies leave opportunity for adjunctive agents for MDD and for monotherapies targeting specific patient subpopulations, particularly those with treatment-resistant depression (TRD) or residual symptoms of depression.<\/p>\n","protected":false},"template":"","class_list":["post-391371","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-unipolar-depression","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391371\/revisions"}],"predecessor-version":[{"id":394494,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391371\/revisions\/394494"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}